- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prevention of COVID-19 caused by SARS-CoV-2
- Meeting Date: May 2026
- Public Summary Document (PSD) May 2025 December 2025 May 2026 PBAC Meetings – (PDF 2.2KB)
- Public Summary Document (PSD) May 2025 December 2025 May 2026 PBAC Meetings – (Word 1.9KB)
Raxtozinameran (BNT162b2 mRNA COVID-19 vaccine) – May 2025 – December 2025 – May 2026
Raxtozinameran: I.M. injection, suspension for injection containing raxtozinameran 30 micrograms; Comirnaty® Omicron XBB.1.5
Last updated
9 May 2025